Research and development

Lundbeck's research and development (R&D) efforts are dedicated to creating new and innovative pharmaceuticals for the treatment of brain diseases. Through investment and perseverance, we strive to create the very best treatments for patients.

Research is our foundation

Lundbeck is the only fully-integrated pharmaceutical company in the world, solely devoted to the treatment of brain diseases.  We dedicate our entire R&D efforts to develop innovative drugs for treatment of a number of psychiatric and neurological diseases.  Our R&D projects focus on:

  • Alcohol dependence
  • Alzheimer’s disease
  • Bipolar disorder
  • Depression and anxiety
  • Epilepsy
  • Huntington’s disease
  • Lennox-Gastaut syndrome
  • Parkinson's disease
  • Psychosis

Read more about our disease areas

Underlying disease biology

Lundbeck's R&D strategy is aimed at enabling the discovery and development of new pharmaceuticals targeting the underlying mechanisms of brain diseases.  This approach allows us to treat the symptoms more effectively and potentially also to alter the course of the diseases.  The strategy requires comprehensive research into the brain and the biology and mechanisms of brain diseases, as well as improved understanding of research targets and clinical outcomes.

Strategic partnerships

Essential to the R&D strategy is for Lundbeck to maintain strong internal R&D capabilities in order to establish optimal networks and partnerships. We will continue to build external alliances to supplement our internal capabilities, taking advantage of the increased opportunities provided by innovative technologies. Our partnership structure allows us to run an extensive co-development on pipeline projects, particularly in our partnerships with Takeda Pharmaceutical Co. Limited and Otsuka Pharmaceutical Co., Ltd.  The structure enables Lundbeck to have more development projects running in tandem, whilst being able to invest considerably more than what is directly available from our R&D resources.

Future platform

Our R&D strategy will provide a future platform from which Lundbeck can discover and develop drugs with clearly documented effects on biologically defined patient groups.  It is expected that society’s demand for these new type of drugs will increase. Currently, Lundbeck reinvests approximately 20% of its revenue in R&D on an annual basis.

Go to our pipeline

Our R&D organization

As a medium-sized pharmaceutical company, we share common values in the way we work worldwide and keep a clear focus in our R&D strategy.  Research at Lundbeck is based on the efforts of our multi-disciplinary, empowered project teams, our in-house expertise in the brain disease area and our state-of-the-art technologies.  We work in new, well-equipped laboratories. In each project team, we integrate our advanced knowledge in R&D disciplines with expertise in clinical practices and therapeutic needs.

Global presence

Our R&D organization is international and consists of more than 1,300 dedicated R&D staff.  The research organisation is located in Copenhagen, Denmark, in New Jersey, US and in Shanghai, China. Development headquarters are situated in Copenhagen, Denmark with clinical research and regulatory personnel spread worldwide.

Respect for the individual

At Lundbeck R&D, we work together as individuals towards common goals.  We seek to constantly develop and improve our scientific and personal skills and qualifications.  This allows us to promote career opportunities for the individual, as well as maintain and develop our competencies as an organization.  Publication of our scientific results is a natural part of our participation as active members in the international scientific community.

Go to the list of our publications

Development of a new pharmaceutical product


 No. of molecules / No. of patients

 Read more about the development process





Cookie Policy
You are about to leave the website.